A website to provide support for people who have or have had any type of cancer, for their caregivers and for their family members.
Page 1 of 8 123 ... LastLast
Results 1 to 10 of 74

Thread: (L) Hormone Therapy

  1. #1

    (L) Hormone Therapy

    Table of Contents
    A title in all caps does not reflect any emphasis; it is simply how it appeared on the page I copied from.
    Studies in red are new additions.

    [#1] Impact of Androgen Deprivation Therapy on Self-reported Cognitive Function in Men with Prostate Cancer [2018]

    [#2] Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation [2017]

    [#3] Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy [2017]

    [#4] Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis [2018]

    [#5] Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer [2016]

    [#6] Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study [2018]

    [#7] Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial [2018]

    Exercise Interventions for Prostate Cancer Survivors Receiving Hormone Therapy: Systematic Review [2017]

    [#8] Estrogens and Their Receptors in Prostate Cancer: Therapeutic Implications [2018]

    [#9] Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard [2018]



    [#12] Safety of Testosterone Therapy in a Large Clinical Cohort of Men with Prostate Cancer [2018]

    [#13] Integrating diet and exercise into care of prostate cancer patients on androgen deprivation therapy [2016]

    [#14] Effect of androgen deprivation therapy on sexual function and bother in men with prostate cancer: A controlled comparison [2017]

    [#15] Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer [2018]

    [#16] Effects of Different Exercise Modalities on Fatigue in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: A Year-long Randomised Controlled Trial [2017]

    [#17] Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement [2017]

    [#18] Androgen Receptor-Targeted Treatments for Prostate Cancer: 35 Years' Progress with Antiandrogens [2018]

    [#19] First-line use of novel hormonal agents in prostate cancer: a critical appraisal [2018]

    [#20] Association between Androgen Deprivation Therapy and Patient-Reported Depression in Men with Recurrent Prostate Cancer [2018]

    [#21] Body composition, fatigue and exercise in patients with prostate cancer undergoing androgen deprivation therapy [2018]

    [#22] Evaluation of the Efficacy and Side-Effects of Androgen Deprivation Therapy in Nonmetastatic Prostate Cancer [2018]

    [#23] Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy [2018]

    [#24] Androgen deprivation therapy (ADT) and cardiovascular mortality (CVD) in men with early-stage prostate cancer (PC) receiving curative radiation therapy (RT) [2018]

    [#25] The influence of an androgen deprivation therapy educational program on dyadic quality and intimacy for prostate cancer patients and their partners [2018]

    [#26] Association Between Androgen Deprivation Therapy and Patient-reported Depression in Men With Recurrent Prostate Cancer [2018]

    [#27] Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer [2018]

    [#28] Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality [2018]

    [#29] New-onset diabetes after androgen-deprivation therapy for prostate cancer: A nationwide propensity score-matched four-year longitudinal cohort study [2018]

    [#30] Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels [2018]

    [#31] The Role of Testosterone Therapy in the Setting of Prostate Cancer [2018]

    [#32] Risk of diabetes complications among those with diabetes receiving androgen deprivation therapy for localized prostate cancer [2018]

    [#33] Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial [2018]

    [#34] Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis [2018]

    [#35] Null association between androgen-deprivation therapy and nonprostate cancer mortality among older men with nonmetastatic prostate cancer [2018]

    [#36] Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia [2017]

    [#37] Eighteen Months of Androgen Deprivation Therapy in Men with High-risk Prostate Cancer and the Risk of Death [2018]

    [#38] Immediate vs. Delayed ADT for Recurrent Prostate Cancer [2018]

    [#39] Risks of Major Long-term Side Effects Associated with Androgen Deprivation Therapy in Men with Prostate Cancer [2018]

    [#40] Is Androgen Deprivation Therapy “Another Deficient Therapy” for Gleason Score 9-10 Prostate Cancer? [2018]

    [#41] Is Gleason Grade 5 Prostate Cancer Resistant to Conventional Androgen Deprivation Therapy? [2016]

    [#42] Nutrition care guidelines for men with prostate cancer undergoing androgen deprivation therapy: do we have enough evidence? [2018]

    [#43] The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer [2018]

    [#44] What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations [2018]


    [#46] Androgen deprivation therapy in prostate cancer: new findings and questions for the future [2018]

    [#47] Testosterone, testosterone therapy and prostate cancer [2019]


    [#49] Androgen deprivation therapy in nonmetastatic prostate cancer patients: Indications, treatment effects, and new predictive biomarkers [2019]

    [#50] Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy [2019]

    [#51] How Are Patients With Prostate Cancer Managing Androgen Deprivation Therapy Side Effects? [2018]

    [#52] Revisiting Intermittent Therapy in Metastatic Prostate Cancer Can Less be More in the “New World Order?” [2019]

    [#53] Prostate Cancer Patients' Preferences for Intermittent vs. Continuous Androgen Deprivation—A Pilot Institutional Study [2019]

    [#54] Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review [2019]

    [#55] Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer [2019]

    [#56] Androgen deprivation therapy and Gleason grade: unravelling implications on survival [2019]

    Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes A Systematic Review and Patient-Level Meta-analysis [2019]

    [#57] Cancer-related symptoms, mental well-being, and psychological distress in men diagnosed with prostate cancer treated with androgen deprivation therapy [2019]

    [#58] Body Image Issues and Attitudes Toward Exercise amongst Men Undergoing Androgen Deprivation Therapy (ADT) Following Diagnosis of Prostate Cancer [2019]

    [#59] Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer [2019]

    [#60] The ABCs of Androgen Deprivation Therapy - 2019 Prostate Cancer Patient Conference [2019]

    [#61] Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer [2019]

    [#62] Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis [2019]

    [#63] Prognostic value of testosterone during androgene deprivation therapy [2019]

    [#64] How Are Patients With Prostate Cancer Managing Androgen Deprivation Therapy Side Effects? [2019]

    [#65] Safety of testosterone therapy in men with prostate cancer [2019]

    [#66] Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer [2019]

    Since October:

    [#67] Responsiveness to Resistance-Based Multimodal Exercise Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy [2019]

    [#68] New Protocol of Intermittent Androgen Deprivation Therapy for Patients With Metastatic Prostate Cancer: A Retrospective Study [2019]

    [#69] 68Ga-prostate-specific membrane antigen PETCT-based response to androgen deprivation therapy in patients with prostate cancer [2019]

    Last edited by DjinTonic; 11-05-2019 at 01:50 PM.

  2. #2
    [Table of Contents p.2]

  3. #3
    [Table of Contents p.3]

  4. #4
    [Table of Contents p.4]

  5. #5
    [Table of Contents p.5]

  6. #6
    Impact of Androgen Deprivation Therapy on Self-reported Cognitive Function in Men with Prostate Cancer [2018]



    Although androgen deprivation therapy (ADT) is widely used to treat prostate cancer (PC), its effects on cognitive function are unclear, and no prior report has examined the impact of ADT on self-reported cognitive function.

    Three groups of men age 50 or older and matched on age and education were enrolled: PC patients starting continuous ADT (n=81), PC patients not receiving ADT (PC controls, n=84), and healthy controls (n=85). Two scales from the Functional Assessment of Cancer Therapy-Cognitive Questionnaire (FACT-Cog) version 3 were used to assess self-reported cognitive function. Changes in cognitive scores over time were analyzed using two approaches: multivariable regression and calculation of the proportion of subjects per group with declines of 1-SD or more. Multivariable regression was used to assess predictors of decline in self-reported cognitive function. Relationships between the FACT-Cog and a neuropsychological battery of 15 tests were also examined.

    The mean age of participants was 69 years (range 50-87) and their mean educational level was 15 years (range 8-24). FACT-Cog scores were similar at baseline across cohorts. Neither analytic approach found ADT use to be associated with changes in self-reported cognitive function on either FACT-Cog scale. Mood and fatigue were correlated with changes in self-reported cognitive function. The relationship between self-reported and objective cognitive measures was weak (maximum Spearman correlation coefficient of 0.14) and only two of 30 correlations were statistically significant.

    Twelve months of ADT was not associated with self-reported cognitive function in older men with non-metastatic PC.
    [Emphasis mine]

    First Forum post: https://www.cancerforums.net/threads/54428-Impact-of-ADT-on-Self-reported-Cognitive-Function-in-Men-with-PCa

  7. #7
    Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation [2017]


    In men with prostate-specific antigen failure after radical radiotherapy, androgen deprivation therapy should be delayed until the site of recurrence is known to allow consideration of curative treatment options, to delay androgen deprivation therapy-related morbidity, and to enable earlier access to abiraterone and docetaxel.

    Men with prostate-specific antigen (PSA) failure after radical radiotherapy for localised prostate cancer are often managed with early androgen deprivation therapy (ADT). However, the optimum timing of starting ADT is uncertain. Debate about the timing of ADT is not new [1], but has been revived by the results of the Timing of Androgen Deprivation (TOAD) trial [[2], [3]]. Here we describe the rationale for delaying ADT in men with PSA-only failure after radiotherapy. Our arguments relate specifically to the use of ADT alone after prior radical radiotherapy. They do not apply to the use of early ADT as an adjuvant to postoperative radiotherapy, for which there is a growing body of evidence [4].
    [Emphasis mine]

    First Forum post: https://www.cancerforums.net/threads/53857-BCR-after-Prostate-Radiotherapy-The-Case-Against-Early-Androgen-Deprivation

  8. #8
    Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy [2017]


    We studied trends in androgen deprivation therapy (ADT) use with salvage radiation.
    From 2004 through 2012, 32.1% of salvage radiation patients received ADT.
    ADT use rose to 6% with the 2010 reporting of a metastasis benefit by RTOG 9601.
    •Higher Gleason score, pT3–4 stage, and positive margins were predictors of ADT use.

    OBJECTIVE: The RTOG 9601 and GETUG-AFU 16 randomized controlled trials demonstrated that the addition of androgen deprivation therapy (ADT) to salvage radiation therapy (SRT) improves progression-free and, for RTOG 9601, overall survival. We examined national trends in the use of ADT with SRT.

    RESULTS: Overall, 32.1% of SRT patients received ADT, which increased after initial results of RTOG 9601 showed an improvement in metastasis-free survival in 2010 (28.5% in 2008/2009 vs. 34.5% in 2011/2012, P = 0.006). Predictors of ADT use include presurgery prostate-specific antigen>20ng/ml vs.<10ng/ml (adjusted odds ratio [AOR] = 1.34, P = 0.002; 36.7% vs. 29.6%); positive vs. negative margins (AOR = 1.29, P = 0.001; 34.9% vs. 27.8%); Gleason 3+4 (AOR = 1.53; 21.3%), Gleason 4+3 (AOR = 2.40; 32.0%), or Gleason 8 to 10 (AOR = 4.49; 49.2%) vs. Gleason 2 to 6 (P≤0.005 for all; 13.2%); and pathologic T3a (AOR = 1.46; 30.9%), T3b (AOR = 2.50; 47.6%), or T4 (AOR = 4.14; 60.9%) vs. T2 (P<0.001 for all; 19.1%). Starting SRT 12 to 23.9 months (AOR = 0.69; 23.2%) or≥24 months (AOR = 0.25; 8.0%) after RP was associated with decreased odds of ADT use vs. starting SRT 6 to 8.9 months after RP (P≤0.002 for both; 35.0%).

    CONCLUSION: Although less than one-third of SRT patients from the study era received ADT, there is evidence that physicians and patients have begun slowly adopting this practice with the 2010 reporting of a decrease in the cumulative incidence of metastases with the addition of ADT to SRT. Given the newly reported survival benefit of RTOG 9601, additional work will be necessary to identify which patients benefit the most from the use of ADT with SRT to individualize treatment.
    [Emphasis mine]

    First Forum post: https://www.cancerforums.net/threads/53350-Who-benefits-from-adding-ADT-to-SR-A-review-of-4200-patients-who-received-SRT

  9. #9
    Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis [2018]


    Androgen receptor is the major driver of and testosterone the natural growth factor of prostate cancer (PC). Studies exploring the relationship among circulating testosterone levels, PC aggressiveness, and patient prognosis showed contradictory results. We performed a comprehensive literature search for studies reporting the independent relationship between serum testosterone and prognosis of PC patients. Meta-analyses using random effects models were conducted to estimate pooled hazard ratios (HRs) and 95% confidence intervals (CIs). We identified 25 articles that evaluated the prognostic value of testosterone in early-stage PC (8 studies), in advanced PC either before (4 studies) or during androgen deprivation therapy (ADT) (5 studies), and in castration-resistant PC (8 studies). [U]In early PC, serum testosterone level was not prognostic in terms of overall survival (HR = 1.03; 95% CI, 0.99-1.08; P = .19) and biochemical recurrence (HR = 0.99; 95% CI, 0.87-1.13; P = .93). In advanced PC, higher testosterone levels before ADT were associated with a reduced risk of death (HR = 0.58; 95% CI, 0.45-0.74; P < .0001). During ADT, lower levels were associated with a reduced risk of death (HR = 0.48; 95% CI, 0.28-0.81; P = .006) and progression (HR = 0.59; 95% CI, 0.46-0.77; P < .0001). In castration-resistant PC patients, higher testosterone levels predicted a reduced risk of progression (HR = 0.33; 95% CI, 0.11-0.97; P = .04) but not of death (HR = 0.86; 95% CI, 0.69-1.07; P = .18 ). The heterogeneity of the included studies is a major limitation of this meta-analysis. The relationship between circulating testosterone and PC prognosis varies in different clinical settings and according to ADT administration.
    [Emphasis mine]
    Last edited by DjinTonic; 04-12-2018 at 01:26 AM.

  10. #10
    Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer
    [2016, Full Text]



    Androgen deprivation therapy (ADT) for prostate cancer (PCa) increases risk of type 2 diabetes (T2DM); however the association between types and duration of ADT has not been fully elucidated. We examined how type and duration of ADT affects risk of T2DM. Using data from Prostate Cancer database Sweden (PCBaSe) we investigated risk of T2DM in a cohort of 34,031 men with PCa on ADT; i.e., anti‐androgens (AA), orchiectomy, or gonadotropin‐releasing hormone (GnRH) agonists compared to an age‐matched, PCa‐free comparison cohort (n = 167,205) using multivariate Cox proportional hazard regression. T2DM was defined as a newly filled prescription for metformin, sulphonylurea, or insulin in the Prescribed Drug Register. A total of 21,874 men with PCa received GnRH agonists, 9,143 AA and 3,014 underwent orchiectomy. Risk of T2DM was increased in men in the GnRH agonists/orchiectomy group during the first 3 years of ADT [i.e., 1 − 1.5 years HR: 1.61 (95%CI: 1.36 − 1.91)], compared to PCa‐free men. The risk decreased thereafter (e.g., 3 − 4 years HR: 1.17 (95% CI: 0.98 − 1.40)). Conversely, no increased risk was seen in men on AA (HR: 0.74 (95%CI: 0.65 − 0.84). The incidence of T2DM per 1,000 person‐years was 10 for PCa‐free men, 8 for men on AA, and 13 for men on GnRH agonists/orchiectomy. Duration of ADT has a significant impact on risk of T2DM. With the peak after three years of treatment, our data indicates that men on ADT, even for a limited period of time, such as adjuvant to radiotherapy, are at increased risk of T2DM.

    Duration of GnRH agonists had a significant impact on risk of T2DM in men with PCa, with the peak risk observed after 3 years of treatment. This suggests that even men receiving adjuvant ADT, for a short time period, may be at increased risk of T2DM.


Similar Threads

  1. Replies: 10
    Last Post: 03-03-2018, 03:20 PM
  2. hormone treatement at Advanced Stage-Hormone Refractory
    By sophia in forum Prostate Cancer Forum
    Replies: 1
    Last Post: 09-29-2009, 02:05 PM
  3. Hormone therapy and no Chemo?
    By francis in forum Breast Cancer Forum
    Replies: 6
    Last Post: 07-13-2005, 02:43 PM
  4. Replies: 0
    Last Post: 07-01-2005, 04:00 AM
  5. Replies: 0
    Last Post: 05-16-2005, 12:55 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts